U.S. markets closed

Intellia Therapeutics, Inc. (NTLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
78.91-0.31 (-0.39%)
At close: 4:00PM EDT
78.91 0.00 (0.00%)
After hours: 05:17PM EDT

Intellia Therapeutics, Inc.

40 Erie Street
Suite 130
Cambridge, MA 02139
United States
857 285 6200

Full Time Employees312

Key Executives

NameTitlePayExercisedYear Born
Dr. John M. LeonardPres, CEO & Director912.79k4.05M1957
Mr. Glenn G. GoddardExec. VP, CFO & Treasurer562.45kN/A1971
Dr. Andrew D. SchiermeierExec. VP & COO637.38k64.65k1970
Dr. Laura Sepp-LorenzinoExec. VP & Chief Scientific Officer609.38kN/A1961
Dr. David Lebwohl M.D.Exec. VP & Chief Medical Officer529.07kN/AN/A
Mr. Nessan Bermingham Ph.D.Founder & Member of Scientific Advisor BoardN/AN/A1973
Dr. Rachel HaurwitzCo-FounderN/AN/A1986
Dr. Andrew MayFounder and Member of Scientific Advisor BoardN/AN/AN/A
Dr. Jennifer A. DoudnaFounder & Member of Scientific Advisor BoardN/AN/A1964
Dr. Derrick J. RossiFounder & Member of Scientific Advisor BoardN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Intellia Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.